Читать книгу Parathyroid Disorders - Группа авторов - Страница 56

1Silverberg SJ, Lewiecki EM, Mosekilde L, Peacock M, Ribin MR: Presentation of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J Clin Endocrinol Metab 2009;94:351–365.

2Touvier M, Deschasaux M, Montourcy M, Sutton A, Charnuax N, Kess-Guyot E, Fezeu LK, Latino-Martel P, Druesne-Pecollo N, Malvy D, Galan P, Hercberg S, Ezzedine K, Souberbielle JC: Interpretation of plasma PTH concentrations according to 25OHD status, gender, age, weight status, and calcium intake: importance of the reference values. J Clin Endocrinol Metab 2014;99:1196–1203.

3Souberbielle JC, Cormier C, Kindermans C, Gao P, Cantor T, Forette F, Baulieu EE: Vitamin D status and redefining serum parathyroid hormone reference range. J Clin Endocrinol Metab 2001;86:3086–3090.

4Souberbielle JC, Fayol V, Sault C, Lawson-Body E, Kahan A, Cormier A: Assay-specific decision limits for two new automated parathyroid hormone and 25-hydroxyvitamin D assays. Clin Chem 2005;51:395–400.

5Harvey A, Hu M, Gupta M, Butler R, Mitchell J, Berber E, Siperstein A, Milas M: A new, vitamin D-based, multidimensional nomogram for the diagnosis of primary hyperparathyroidism. Endocr Pract 2012;18:124–131.

6Rajhbeharrysingh U, El Youssef J, Leon E, Lasarev MR, Klein R, Vanek C, Mattar S, Berber E, Siperstein A, Shindo M, Milas M: Expanding the net: the re-evaluation of the multidimensional nomogram calculating the upper limit of normal PTH (maxPTH) in the setting of secondary hyperparathyroidism and the development of the MultIdimensional Predictive Hyperparathyroid model (Mi-PTH). Surgery 2016;159:226–239.

7Lavryk OA, Siperstein AE: Use of calcium and parathyroid hormone nomogram to distinguish between atypical primary hyperparathyroidism and normal patients. World J Surg 2017;41:122–128.

8Cao S, Hu Y, Zhao Y, Su Z, Xu Z, Gao X, Liao Q, Zhao Y: A retrospective study of elevated post-operative parathormone in primary hyperparathyroid patients. Oncotarget 2017;8:101158–101164.

9Cusano NE, Maalouf NM, Wang PY, Zhang C, Cremers SC, Haney EM, Bauer DC, Orwoll ES, Bilezikian JP: Normocalcemic hyperparathyroidism and hypoparathyroidism in two community-based nonreferral populations. J Clin Endocrinol Metab 2013;98:2734–2741.

10Vignali E, Cetani F, Chiavistelli S, Meola A, Saponaro F, Centoni R, Cianferotti L, Marcocci C: Normocalcemic primary hyperparathyroidism: a survey in a small village of Southern Italy. Endocr Connect 2015;4:172–178.

11Lundgren E, Rastad J, Thrufjell E, Akerstrom G, Ljunghall S: Population-based screening for primary hyperparathyroidism with serum calcium and parathyroid hormone values in menopausal women. Surgery 1997;121:287–294.

12Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M: Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine 2012;42:764–766.

13Majid H, Khan AH, Riaz M, Karimi H, Talati J: Identifying parathyroid hormone disorders and their phenotypes through a bone health screening panel: it’s not simple vitamin D deficiency! Endocr Pract 2016;22:814–821.

14Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, Siris E, Udesky J, Silverberg SJ: The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 2008;93:3462–3470.

15Ho C, Conner DA, Pollak MR, Ladd DJ, Kifor O, Warren HB, Brown EM, Seidman JG, Seidman CE: A mouse model of human familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Nat Genet 1995;11:389–394.

16Mallya SM, Gallagher JJ, Wild YK, Kifor O, Costa-Guda J, Saucier K, Brown EM, Arnold A: Abnormal parathyroid cell proliferation precedes biochemical abnormalities in a mouse model of primary hyperparathyroidism. Mol Endocrinol 2005;19:2603–2609.

17Libutti SK, Crabtree JS, Lorang D, Burns AL, Mazzanti C, Hewitt SM, O’Connor S, Ward JM, Emmert-Buck MR, Remaley A, Miller M, Turner E, Alexander HR, Arnold A, Marx SJ, Collins FS, Spiegel AM: Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res 2003;63:8022–8028.

18Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism. Arq Bras Endocrinol Metabol 2010;54:106–109.

19Bordier P, Ryckewart A, Gueris J, Rasmussen H: On the pathogenesis of the so-called idiopathic hypercalciuria. Am J Med 1977;63:398–409.

20Palmieri S, Eller-Vainicher C, Cairoli E, Morelli V, Zhukouskaya VV, Verga U, Filopanti M, Vicentini L, Ferrero S, Spada A, Chiodini I: Hypercalciuria may persist after successful parathyroid surgery and it is associated with parathyroid hyperplasia. J Clin Endocrinol Metab 2015;100:2734–2742.

21Maruani G, Hertig A, Paillard M, Houillier P: Normocalcemic primary hyperparathyroidism: evidence for a generalized target-tissue resistance to parathyroid hormone. J Clin Endocrinol Metab 2003;88:4641–4648.

22Balenga N, Azimzadeh P, Hogue JA, Staats PN, Shi Y, Koh J, Dressman H, Olson JA Jr: Orphan adhesion GPCR GPR64/ADGRG2 is overexpressed in parathyroid tumors and attenuates calcium-sensing receptor-mediated signaling. J Bone Miner Res 2017;32:654–666.

23Díaz-Soto G, Romero E, Castrillón JL, Jauregui OI, de Luis Román D: Clinical expression of calcium sensing receptor polymorphism (A986S) in normocalcemic and asymptomatic hyperparathyroidism. Horm Metab Res 2016;48:163–168.

24Díaz-Soto G, Romero E, Pérez-Castrillón JL, Jauregui OI, de Luis Román D: Parathyroid hormone polymorphism RS6254 is associated with the development and severity of osteoporosis in asymptomatic but not normocalcemic hyperthyroidism. Horm Metab Res 2016;48:828–833.

25Bilezikian JP, Brandi ML, Eastell R, Silverberg SJ, Udelsman R, Marcocci C, Potts JT Jr: Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the Fourth International Workshop. J Clin Endocrinol Metab 2014;99:3561–3569.

26Forster J, Monchik JM, Martin HF: A comparative study of serum ultrafiltrable, ionized, and total calcium in the diagnosis of primary hyperparathyroidism in patients with intermittent or no elevation in total calcium. Surgery 1998;104:1137–1142.

27Som M, Stroup JS: Primary hyperparathyroidism and pregnancy. Proc Bayl Univ Med Cent 2011;24:220–223.

28Eisner B, Ahn J, Stoller M: Differentiating primary from secondary hyperparathyroidism in stone patients: the “Thiazide challenge”. J Endourol 2009;23:191–192.

29Hagag P, Revet-Zak I, Hod N, Horne T, Rapoport MJ, Weiss M: Diagnosis of normocalcemic hyperparathyroidism by oral calcium loading test. J Endocrinol Invest 2003;26:327–332.

30Gallieni M, De Luca N, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Dal Canton A, Minutolo R: Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. J Nephrol 2016;29:71–78.

31Lowe H, McMahon DJ, Rubin MR, Bilezikian JP, Silverberg SJ: Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab 2007;92:3001–3005.

32Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F: Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos 2012;2012:128352.

33Charopoulos I, Tournis S, Trovas G, Raptou P, Kaldrymides P, Skarandavos G, Katsalira K, Lyritis GP: Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab 2006;91:1748–1753.

34Díaz-Soto G, de Luis Román D, Jauregui OI, Briongo L, Romero E, Pérez-Castrillón JL: Trabecular bone score in patients with normocalcemic hyperparathyroidism. Endocr Pract 2016;22:703–707.

35Chen G, Xue Y, Zhang Q, Xue T, Yao J, Huang H, Liang J, Li L, Lin W, Lin L, Shi L, Cai L, Wen J: Is normocalcemic primary hyperparathyroidism harmful or harmless? J Clin Endocrinol Metab 2015;100:2420–2424.

36Corbetta S, Mantovani G, Spada A: Metabolic syndrome in parathyroid diseases. Front Horm Res 2018;49:144–159.

37Mesquita PN, Dornelas Leão Leite AP, Chagas Crisostomo SD, Veras Filho E, da Cunha Xavier L, Bandeira F: Evaluation of coronary calcium score in patients with normocalcemic primary hyperparathyroidism. Vasc Health Risk Manag 2017;13:225–229.

38Pepe J, Cipriani C, Sonato C, Raimo O, Biamonte F, Minisola S: Cardiovascular manifestations of primary hyperparathyroidism: a narrative review. Eur J Endocrinol 2017;177:R297–R308.

39van Ballegooijen AJ, Reinders I, Visser M, Brouwer IA: Parathyroid hormone and cardiovascular disease events: a systematic review and meta-analysis of prospective studies. Am Heart J 2013;165:655–664.

40Billington EO, Gamble GD, Reid IR: Parathyroid hormone reflects adiposity and cardiometabolic indices but not bone density in normal men. Bonekey Rep 2016;5:852.

41Cakir I, Unluhizarci K, Tanriverdi F, Elbuken G, Karaca Z, Kelestimur F: Investigation of insulin resistance in patients with normocalcemic primary hyperparathyroidism. Endocrine 2012;42:419–422.

42Tassone F, Maccario M, Gianotti L, Baffoni C, Pellegrino M, Cassibba S, Cesario F, Magro G, Borretta G: Insulin sensitivity in normocalcaemic primary hyperparathyroidism. Endocrine 2013;44:812–814.

43Diri H, Unluhizarci K, Kelestimur F: Investigation of glucose intolerance in patients with normocalcemic primary hyperparathyroidism: 4-year follow-up. Endocrine 2014;47:971–972.

44Hirsch D, Kopel V, Nadler V, Levy S, Toledano Y, Tsvetov G: Pregnancy outcomes in women with primary hyperparathyroidism. J Clin Endocrinol Metab 2015;100:2115–2122.

45Lim JY, Herman MC, Bubis L, Epelboym I, Allendorf JD, Chabot JA, Lee JA, Kuo JH: Differences in single gland and multigland disease are seen in low biochemical profile primary hyperparathyroidism. Surgery 2017;161:70–77.

46Campennì A, Ruggeri RM, SIndoni A, Giovinazzo S, Calbo E, Ieni A, Calbo L, Tuccari G, Baldari S, Benvenga S: Parathyroid carcinoma presenting as normocalcemic hyperparathyroidism. J Bone Miner Metab 2012;30:367–372.

47Rejnmark L, Amstrup AK, Mollerup CL, Heickendorff L, Mosekilde L: Further insights into the pathogenesis of primary hyperparathyroidism: a nested case-control study. J Clin Endocrinol Metab 2013;98:87–96.

48Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, Borderie D, Kahan A, Cormier C: Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab 2013;98:3213–3220.

49Koumakis E, Souberbielle JC, Payet J, Sarfati E, Borderie D, Kahan A, Cormier C: Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism. Osteoporos Int 2014;25:1963–1968.

50Wade TJ, Yen TW, Amin AL, Wang TS: Surgical management of normocalcemic primary hyperparathyroidism. World J Surg 2012;36:761–766.

51Marcocci C, Bollerslev J, Khan AA, Shoback DM: Medical management of primary hyperparathyroidism: proceedings of the Fourth International Workshop on the Management of Asymptomatic Primary Hyperparathyroidism. J Clin Endocrinol Metab 2014;99:3607–3618.

52Cesareo R, Di Stasio E, Vescini F, Campagna G, Cianni R, Pasqualini V, Romitelli F, Grimaldi F, Manfrini S, Palermo A: Effects of alendronate and vitamin D in patients with normocalcemic primary hyperparathyroidism. Osteoporos Int 2015;26:1295–1302.

53Konrade I, Dambrova G, Dambrova M: Denosumab-induced hypophosphataemia in a case of normocalcaemic primary hyperparathyroidism. Intern Med J 2017;47:974–975.

Prof. Sabrina Corbetta

Endocrinology and Diabetology Service and Laboratory of Experimental Endocrinology

Department of Biomedical Sciences for Health, University of Milan

IRCCS Istituto Ortopedico Galeazzi

Via R. Galeazzi 4 , IT–20161 Milan (Italy)

E-Mail sabrina.corbetta@unimi.it